Owned by the Association for International Promotion & Study in Tumors (APSIT)
Articles
Page 9 of 79
-
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:211
-
Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment
Despite tremendous progress in deciphering breast cancer at the genomic level, the pronounced intra- and intertumoral heterogeneity remains a major obstacle to the advancement of novel and more effective treat...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:210 -
LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA network
Prostate cancer threatens the health of men over sixty years old, and its incidence ranks first among all urinary tumors among men. Enzalutamide remains the first-line drug for castration-resistant prostate ca...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:209 -
Correction: MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:208 -
Global serum profiling: an opportunity for earlier cancer detection
The advances in cancer research achieved in the last 50 years have been remarkable and have provided a deeper knowledge of this disease in many of its conceptual and biochemical aspects. From viewing a tumor a...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:207 -
Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment
The perineural invasion (PNI)-mediated inflammation of the tumor microenvironment (TME) varies among gastric cancer (GC) patients and exhibits a close relationship with prognosis and immunotherapy. Assessing t...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:206 -
CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
Glioblastoma (GBM) is the most common malignant brain tumor and has “immunologically cold” features. Changing GBM to an “immunologically hot” tumor requires a strong trigger that induces initial immune respons...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:205 -
AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer
Prostate cancer(PCa) is the most commonly occurring male cancer in the USA. Abiraterone or Enzalutamide have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). However, ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:204 -
Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis
TP53, encoding the tumor suppressor p53, is frequently mutated in various cancers, producing mutant p53 proteins (mutp53) which can exhibit neomorphic, gain-of-function properties. The latter transform p53 into a...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:203 -
Correction: PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:202 -
Fibronectin fragments generated by pancreatic trypsin act as endogenous inhibitors of pancreatic tumor growth
The pancreatic microenvironment has a defensive role against cancer but it can acquire tumor-promoting properties triggered by multiple mechanisms including alterations in the equilibrium between proteases and...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:201 -
An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer
Advanced colorectal cancer (CRC) is difficult to treat. For that reason, the development of novel therapeutics is necessary. Here we describe a potentially actionable plasma membrane target, the amino acid tra...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:200 -
Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance
Gemcitabine resistance (GR) is a significant clinical challenge in pancreatic adenocarcinoma (PAAD) treatment. Macrophages in the tumor immune-microenvironment are closely related to GR. Uncovering the macroph...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:199 -
GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression
Aberrant somatic genomic alteration including copy number amplification is a hallmark of cancer genomes. We previously profiled genomic landscapes of prostate cancer (PCa), yet the underlying causal genes with...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:198 -
Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models
Autotaxin (ATX) is a secreted enzyme that converts lysophosphatidylcholine to lysophosphatidic acid (LPA). LPA stimulates cell proliferation and migration and promotes wound repair following tissue damage. ATX...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:197 -
Anti-VEGF therapy selects for clones resistant to glucose starvation in ovarian cancer xenografts
Genetic and metabolic heterogeneity are well-known features of cancer and tumors can be viewed as an evolving mix of subclonal populations, subjected to selection driven by microenvironmental pressures or drug...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:196 -
TSPAN18 facilitates bone metastasis of prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination
Bone metastasis is a principal cause of mortality in patients with prostate cancer (PCa). Increasing evidence indicates that high expression of stromal interaction molecule 1 (STIM1)-mediated store-operated ca...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:195 -
RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization
RNA binding proteins (RBPs)—regulated gene expression play a vital role in various pathological processes, including the progression of cancer. However, the role of RBP in hepatocellular carcinoma (HCC) remain...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:194 -
Network approach in liquidomics landscape
Tissue-based biopsy is the present main tool to explore the molecular landscape of cancer, but it also has many limits to be frequently executed, being too invasive with the risk of side effects. These limits ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:193 -
Lysosome blockade induces divergent metabolic programs in macrophages and tumours for cancer immunotherapy
Platinum-drugs based chemotherapy in clinic increases the potency of tumor cells to produce M2 macrophages, thus leading to poor anti-metastatic activity and immunosuppression. Lysosome metabolism is critical ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:192 -
ZEB1-mediated biogenesis of circNIPBL sustains the metastasis of bladder cancer via Wnt/β-catenin pathway
Circular RNAs (circRNAs) circularized by back-splicing of pre-mRNA are widely expressed and affected the proliferation, invasion and metastasis of bladder cancer (BCa). However, the mechanism underlying circRN...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:191 -
TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling
Drug resistance limits the treatment effect of cisplatin-based chemotherapy in head and neck squamous cell carcinoma (HNSCC), and the underlying mechanism is not fully understood. The aim of this study was to ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:190 -
The new world of RNA diagnostics and therapeutics
The 5th Workshop IRE on Translational Oncology was held in Rome (Italy) on 27–28 March at the IRCCS Regina Elena National Cancer Institute. This meeting entitled “The New World of RNA diagnostics and therapeut...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:189 -
Sertaconazole-repurposed nanoplatform enhances lung cancer therapy via CD44-targeted drug delivery
Lung cancer is one of the most frequent causes of cancer-related deaths worldwide. Drug repurposing and nano-drug delivery systems are attracting considerable attention for improving anti-cancer therapy. Serta...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:188 -
A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer
Prostate cancer is a major cause of cancer morbidity and mortality in men worldwide. Androgen deprivation therapy (ADT) has proven effective in early-stage androgen-sensitive disease, but prostate cancer gradu...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:187 -
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
The emergence of resistance to the highly successful BCL2-directed therapy is a major unmet need in acute myeloid leukemia (AML), an aggressive malignancy with poor survival rates. Towards identifying therapeu...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:186 -
Correction: Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:185 -
Fructose promotes angiogenesis by improving vascular endothelial cell function and upregulating VEGF expression in cancer cells
Fructose is a very common sugar found in natural foods, while current studies demonstrate that high fructose intake is significantly associated with increased risk of multiple cancers and more aggressive tumor...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:184 -
Super-enhancers complexes zoom in transcription in cancer
Super-enhancers (SEs) consist of multiple typical enhancers enriched at high density with transcription factors, histone-modifying enzymes and cofactors. Oncogenic SEs promote tumorigenesis and malignancy by a...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:183 -
ISG15 and ISGylation modulates cancer stem cell-like characteristics in promoting tumor growth of anaplastic thyroid carcinoma
Anaplastic thyroid carcinoma (ATC) was a rare and extremely malignant endocrine cancer with the distinct hallmark of high proportion of cancer stem cell-like characteristics. Therapies aiming to cancer stem-li...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:182 -
Retraction Note: Long non-coding RNA MACC1-AS1 promoted pancreatic carcinoma progression through activation of PAX8/ NOTCH1 signaling pathway
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:181 -
Correction: Energy stress-induced circZFR enhances oxidative phosphorylation in lung adenocarcinoma via regulating alternative splicing
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:180 -
Correction: M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:179 -
Exploring association of melanoma-specific Bcl-xL with tumor immune microenvironment
Macrophages take center stage in the tumor microenvironment, a niche composed of extracellular matrix and a heterogeneous group of cells, including immune ones. They can evolve during tumor progression and acq...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:178 -
Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches
Colorectal cancer liver metastasis (CRLM) is one of the leading causes of death among patients with colorectal cancer (CRC). Although immunotherapy has demonstrated encouraging outcomes in CRC, its benefits ar...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:177 -
Retraction Note: Integrin-β5, a miR-185-targeted gene, promotes hepatocellular carcinoma tumorigenesis by regulating β-catenin stability
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:176 -
Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion
The mitogen-activated protein kinase (MAPK) signaling pathway is frequently hyperactivated in malignant melanoma and its inhibition has proved to be an efficient treatment option for cases harboring BRAFV600 muta...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:175 -
Retraction Note: Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:174 -
Involvement of lncRNAs in cancer cells migration, invasion and metastasis: cytoskeleton and ECM crosstalk
Cancer is the main cause of death worldwide and metastasis is a major cause of poor prognosis and cancer-associated mortality. Metastatic conversion of cancer cells is a multiplex process, including EMT throug...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:173 -
Bifidobacterium adolescentis induces Decorin+ macrophages via TLR2 to suppress colorectal carcinogenesis
The interplay between gut microbiota and tumor microenvironment (TME) in the pathogenesis of colorectal cancer (CRC) is largely unknown. Here, we elucidated the functional role of B. adolescentis and its possible...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:172 -
Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance
Chemotherapy, radiotherapy, targeted therapy, and immunotherapy are established cancer treatment modalities that are widely used due to their demonstrated efficacy against tumors and favorable safety profiles ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:171 -
Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids
Approximately 20–50% of patients presenting with localized colorectal cancer progress to stage IV metastatic disease (mCRC) following initial treatment and this is a major prognostic determinant. Here, we have...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:170 -
Energy stress-induced circZFR enhances oxidative phosphorylation in lung adenocarcinoma via regulating alternative splicing
Circular RNAs (circRNAs) contribute to multiple biological functions and are also involved in pathological conditions such as cancer. However, the role of circRNAs in metabolic reprogramming, especially upon e...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:169 -
Retraction Note: SIRT6 drives epithelial-to-mesenchymal transition and metastasis in non-small cell lung cancer via snail-dependent transrepression of KLF4
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:168 -
CD271 activation prevents low to high-risk progression of cutaneous squamous cell carcinoma and improves therapy outcomes
Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent form of skin cancer, showing a rapid increasing incidence worldwide. Although most cSCC can be cured by surgery, a sizeable number of cases...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:167 -
Pulmonary interleukin 1 beta/serum amyloid A3 axis promotes lung metastasis of hepatocellular carcinoma by facilitating the pre-metastatic niche formation
Increasing evidence suggests a vital role of the pre-metastatic niche in the formation of distant metastasis of many cancers. However, how the pre-metastatic niche is formed and promotes pulmonary metastasis o...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:166 -
Host obesity alters the ovarian tumor immune microenvironment and impacts response to standard of care chemotherapy
The majority of women with epithelial ovarian cancer (OvCa) are diagnosed with metastatic disease, resulting in a poor 5-year survival of 31%. Obesity is a recognized non-infectious pandemic that increases OvC...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:165 -
The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells
The receptor for advanced glycation-end products (RAGE) and its ligands have been implicated in obesity and associated inflammatory processes as well as in metabolic alterations like diabetes. In addition, RAG...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:164 -
rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses
Autologous tumor cell-based vaccines (ATVs) aim to prevent and treat tumor metastasis by activating patient-specific tumor antigens to induce immune memory. However, their clinical efficacy is limited. Mannan-...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:163 -
Cellular hierarchy framework based on single-cell/multi-patient sample sequencing reveals metabolic biomarker PYGL as a therapeutic target for HNSCC
A growing body of research has revealed the connection of metabolism reprogramming and tumor progression, yet how metabolism reprogramming affects inter-patient heterogeneity and prognosis in head and neck squ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:162
-
-
-
Official journal of the Regina Elena National Cancer Institute, Scientific Director Gennaro Ciliberto, Rome, Italy
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 11.4
5-year Journal Impact Factor: 11.4
Source Normalized Impact per Paper (SNIP): 1.770
SCImago Journal Rank (SJR): 2.806Speed 2023
Submission to first editorial decision (median days): 5
Submission to acceptance (median days): 100Usage 2023
Downloads: 3,003,080
Altmetric mentions: 3,022